ANGNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (2 6月 2023 @ 05:00):

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases...

Stats
本日の出来高	224 803
平均出来高	9 772.00
時価総額	30.11M
EPS	$0 ( 2024-03-15 )
次の収益日	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0989
ATR14	$0.0950 (9.50%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-28	Nissenson Allen	Buy	4 100	Stock Option (right to buy)
2023-12-28	Chudnovsky Yekaterina	Buy	4 100	Stock Option (right to buy)
2023-12-28	Wilson Karen J	Buy	4 100	Stock Option (right to buy)
2023-12-28	Adams Julian	Buy	4 100	Stock Option (right to buy)
2023-12-28	Venkatesan Jay	Buy	4 100	Stock Option (right to buy)

INSIDER POWER
56.49
Last 97 transactions
Buy: 4 979 407 \| Sell: 2 616 033

ボリューム相関

長: 0.38 (neutral)

短: 0.32 (neutral)

Signal:(71.808) Neutral

Angion Biomedica Corp. 相関

10 最も正の相関
MYSZ	0.924
SMFL	0.92
ALXO	0.915
IRBT	0.914
SSPK	0.913
TRIT	0.908
SPCX	0.905
VNDA	0.903
NCBS	0.903
MTP	0.902

10 最も負の相関
CFFE	-0.929
ARIZ	-0.924
LRMR	-0.922
ROCL	-0.922
OTEC	-0.919
FICV	-0.916
OVLY	-0.915
AIB	-0.914
FATP	-0.914
EMLD	-0.914

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Angion Biomedica Corp. 相関 - 通貨/商品

0.62
( weak )

0.56
( weak )

0.00
( neutral )

0.67
( moderate )

0.63
( weak )

-0.58
( weak negative )

Angion Biomedica Corp. 財務諸表

Annual	2022
収益:	$2.30M
総利益:	$2.30M (100.00 %)
EPS:	$-1.850

FY	2022
収益:	$2.30M
総利益:	$2.30M (100.00 %)
EPS:	$-1.850

FY	2021
収益:	$28.31M
総利益:	$27.88M (98.47 %)
EPS:	$-1.930

FY	2020
収益:	$2.88M
総利益:	$1.69M (58.68 %)
EPS:	$-2.78

Financial Reports:

No articles found.

Angion Biomedica Corp.

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.